Study of TUB-040 Given With Standard Ovarian Cancer Drugs in Patients With Fast-growing Ovarian Cancer

The goal of this clinical study is to learn more about the safety, tolerability, and preliminary effectiveness of TUB-040 when given in combination with standard ovarian cancer treatments in participants with high-grade epithelial serous or endometrioid ovarian cancer. This study will also evaluate the appropriate dose of TUB-040 when used with carboplatin (Carbo) and bevacizumab (BEV), including determining the maximum tolerated dose (MTD) in participants with platinum-sensitive ovarian cancer.

Trial Details

NCT ID
NCT07736937
Phase
PHASE1 / PHASE2
Sponsor
Tubulis GmbH
Status
RECRUITING
Cancer Type
High-Grade Serous Ovarian Cancer
Interventions
  • TUB-040 + Carbo + BEV
Locations (sample)
  • Los Angeles, California, United States|34.05223,-118.24368
  • East Brunswick, New Jersey, United States|40.42788,-74.41598
  • New York, New York, United States|40.71427,-74.00597
  • Brussels, Belgium|50.85045,4.34878
  • Ghent, Belgium|51.05,3.71667

Key Eligibility Criteria

  • Female ≥ 18 years of age at the time of the first screening visit
  • Eastern Cooperative Oncology Group (ECOG) performance status (PS) 0 or 1
  • Histologically confirmed advanced high-grade serous or endometrioid epithelial ovarian, fallopian tube or primary peritoneal cancer.
  • Have platinum-sensitive ovarian cancer (PSOC) defined as: Patients who had recurrences (radiologically confirmed) to platinum-based therapy and hav…

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find High-Grade Serous Ovarian Cancer Trials on Trialify →